Imagion Biosystems 2021 Full Year Results

Imagion Biosystems has released its Annual Report for the year ended 31 December 2021. See linked documents below.

2021 Clinical Highlights: 

  • Multiple patients enrolled and completed the MagSense® HER2 Breast Cancer Phase I Study
  • Four clinical sites in VIC, NSW, and QLD are participating in the Phase I Study

2021 Operational Highlights: 

  • Secured new premises expanding R&D and manufacturing capabilities
  • CSIRO funds support prostate cancer preclinical research at Monash University’s Biomedicine Discovery Institute
  • Collaboration with Patrys Limited looks towards a potential new imaging agent for brain cancer
  • Joint Development Agreement with Global Cancer Technology aims to develop nanoparticle technology for treating breast cancer
  • Revenue from sales of IBX’s super-paramagnetic iron oxide nanoparticles to external parties remains steady

2021 Corporate Highlights:

  • Imagion received $2.6 million in R&D tax incentives
  • Cash balance of $13.4 million as of 31 December 2021
  • Exercise of listed options delivering over $5.5 million to the Company
  • Dr. Yalia Jayalakshmi joins IBX as Chief Development Officer

Executive Chairman and CEO Bob Proulx concludes in the Annual Report, “Imagion starts 2022 in a strong financial position with our clinical study well underway and momentum in our research programs. We are looking forward to bringing our Phase I study to conclusion and executing our next phase of development. We are grateful to all our stakeholders – collaborators, patients that participate in the study, employees, and shareholders – for their ongoing support and we look forward to updating you with progress throughout the year.”

Download the 2021 Annual Report 

Download the Investor Presentation

Download Appendix 4E for the year ending 31 December 2021

Download the Results Release

Download the Appendix 4G & Corporate Governance Statement